AI assistant
Adicet Bio, Inc. — Director's Dealing 2023
Jan 26, 2023
34412_dirs_2023-01-26_533f90fa-3e6f-485d-925b-1b699d33544f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2023-01-24
Reporting Person: Aftab Blake (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-24 | Common Stock | A | 26100 | $0.00 | Acquired | 54309 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-24 | Stock Option (Right to Buy) | $9.05 | A | 117200 | Acquired | 2033-01-23 | Common Stock (117200) | Direct |
Footnotes
F1: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F2: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates.